Bevacizumab Combined With High-Dose Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Patients With Advanced Epithelial Ovarian Cancer.

Trial Profile

Bevacizumab Combined With High-Dose Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Patients With Advanced Epithelial Ovarian Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 May 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Gemcitabine; Melphalan; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2012 Planned end date changed from 1 Dec 2014 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 25 Jan 2012 Actual patient number is 13 according to ClinicalTrials.gov.
    • 25 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top